The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Abstract
Semaglutide in type 2 diabetes with chronic kidney disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, semaglutide also significantly reduced the rate of eGFR decline (annual slope difference 1•16 mL/min per 1•73 m², 0•86-1•47), MACE (HR 0•82, 0•68-0•98), and all-cause mortality (HR 0•80, 0•67-0•95)”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [26]
In the citing paper
“Treatment with injectable semaglutide 1 mg once weekly reduced the relative risk for the composite primary outcome (ie, ≥50% eGFR decline, eGFR <15 mL/min per 1•73 m², dialysis or transplant, or death due to kidney disease or cardiovascular disease) by 24% compared with placebo (HR 0•76, 0•66-0•88).26”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [26]
In the citing paper
“Moreover, the GLP-1 receptor agonist, semaglutide reduced the risk of a composite kidney end point in a dedicated kidney outcome trial.11”
From The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity (2025) · cites this paper as [11]
In the citing paper
“semaglutide can reduce the progression of chronic kidney disease in patients with and without diabetes and even in those taking SGLT2 inhibitors [12–14].”
From New drugs for the treatment of obesity: do we need approaches to preserve muscle mass? (2025) · cites this paper as [13]
In the citing paper
“Once-weekly treatment with 1 mg semaglutide reduced the risk of the primary composite outcome by 24% and delayed the progression of kidney dysfunction over a period of 4 years (75).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [75]
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Bikbov, B., Purcell, C. A., Levey, A. S., Smith, M., Abdoli, A., Abebe, M., Adebayo, O. M., Afarideh, M., Agarwal, S. K., Agudelo-Botero, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30045-3 · Cited by 6,648
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Self-citationEffect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Self-citationEmpagliflozin in Patients with Chronic Kidney Disease
The EMPA-KIDNEY Collaborative Group (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2204233 · Cited by 2,754
Cardiovascular events with finerenone in kidney disease and type 2 diabetes
Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110956 · Cited by 1,814
Self-citation
Cited by
Items 1,701–1,800 of 1,871
Protein mediators of chronic kidney disease in Type 2 diabetes: A mendelian randomization study
Liang, K. Y. H., Zheng, T. M., Tan, D., Sasako, T., Ilboudo, Y., Chen, Y., Butler‐Laporte, G., Yoshiji, S., & Richards, J. B. (2026) · PLoS Medicine · doi:10.1371/journal.pmed.1004802 · Cited by 1
“Despite these interventions, some people with diabetes continue to progress to kidney failure [8,9,11].”
Liu, J., Cui, Y., Wang, H., Ye, H., & Zhang, Y. (2026) · Psychogeriatrics · doi:10.1111/psyg.70166
“…fragmentation) [24, 25] and declined frontal executive cognitive function26, combined with a high prevalence of chronic diseases (e.g., hypertension, diabetes) that exacerbate cerebral blood flow reduction and neuroinflammation [26, 27], form the fundamental basis for these persistent symptoms.”
Chen, H., Wu, X., Yuan, M., Ren, F., Liu, T., Yang, L., An, X., & Zhan, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1937754
Ethical Considerations in Islet Xenotransplantation
Hurst, D. J., Tarzy, A., Bobier, C. A., Padilla, L. A., Kögel, J., Merlocco, A. C., & Meier, R. P. H. (2026) · Xenotransplantation · doi:10.1111/xen.70152 · Cited by 1
“Other alternatives such as advanced insulin pumps and closed loop system, new therapies for diabetes [ 61 ], may further reduce the number of candidates for islet xenotransplantation, yet more research is needed before we can confidently assess the feasibility of these alternatives.”
Peptide drugs for obesity and type 2 diabetes mellitus: an overview of clinical trials
Barzgar, H., Darmadi, D., Nafisa, J., Narkulov, S., & Sviridova, M. B. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120772 · Cited by 2
Kraft, L., Latus, J., & Schanz, M. (2025) · Die Nephrologie · doi:10.1007/s11560-025-00844-4
Sonoda, S., Okada, Y., Mita, T., Torimoto, K., Tanaka, K., Sato, F., Katakami, N., Yoshii, H., Nishida, K., Nakayamada, S., et al. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70403
Nuevo algoritmo de redGDPS 2026: de la glucemia al paciente
Soidán, F. J. G., Menéndez, S. A., Lachica, L. Á., Pato, Ó. B., Pradas, N. C., Teixidó, C. H., Vela, N. S., Mera-Gallego, I., & Carretero-Anibarro, E. (2025) · Diabetes práctica · doi:10.52102/diabet/pract.2025.4.art2 · Cited by 1
Kostev, K., Sievert, H., Konrad, M., & Sarabhai, T. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71089
Reprint of: Chronic Kidney Disease in Diabetes: A Clinical Practice Guideline
Tobe, S. W., BAJAJ, H. S., Tangri, N., Jain, R., Pham, T., Beaudin, V., & McFarlane, P. (2025) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2025.12.004
Lovshin, J. A. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag136
Anupama, Y. J. (2026) · APIK Journal of Internal Medicine · doi:10.4103/ajim.ajim_3_26
Glucagon-Like Peptide-1 Receptor Agonists Use Among Reproductive-Aged Women with Type 2 Diabetes
Bailey, S. C., Cameron, N. A., Batio, S., Wismer, G. A., Wolf, M. S., Wallia, A., Schauer, J. M., Gemkow, J. W., Eggleston, A., Tenfelde, S., et al. (2026) · Journal of Women s Health · doi:10.1177/15409996261478007
The ‘astounding’ rise of semaglutide — and what’s next for weight-loss drugs
Nogrady, B. (2026) · Nature · doi:10.1038/d41586-026-00228-1
Trenas, A., Prieto-Laín, N., Velasco, M. Á. P., Padilla-Leiva, C., Pérez-Ruiz, J. M., Ruíz-Rodríguez, F. I., Gómez‐Huelgas, R., Bernal-López, M. R., & Perez-Belmonte, L. M. (2026) · Pharmaceuticals · doi:10.3390/ph19060894 · Cited by 1
“…trial further demonstrated a reduction in major adverse cardiovascular events among overweight or obese individuals with established cardiovascular disease [13], while the FLOW trial reported significant renal and cardiovascular benefits in patients with type 2 DM and chronic kidney disease [14].”
Holliday, M. W., & Navaneethan, S. D. (2026) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000001072
Milder, T. Y., Milder, D. A., & Kam, P. C. A. (2024) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2024.12.014
Qiu, L., Liu, J., & Hu, N. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1870649 · Cited by 4
KDoc-GCN: A TF-IDF-MI-Driven KNN-GCN for Sarcasm Detection on Twitter (X)
Devulapalli, S. K., Mandala, S. K., & Vollala, S. (2025) · International Conference on Sustainable Communication Networks and Application (ICSCNA) · doi:10.1109/icscn67106.2025.11308265
Lanthier, L., Mutchmore, A., Plourde, M.-É., et al. (2024) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2024.07.011
Updates in management of cardiorenal syndrome
Chung, I., Chen, M., Anderson, L., & Banerjee, D. (2026) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000001209
Ambruso, S. L., & Weir, M. R. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.05.027
Zhang, Z., Li, L., Yang, M., Chen, W., Xiao, L., Sun, L., & Agarwal, R. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag179
Acute eGFR Changes With Finerenone Examined in a Prespecified Analysis of FINE-ONE
Cherney, D. Z. I., Yi, T. W., Heerspink, H. J. L., Ji, L., McGill, J. B., Rossing, P., Tuttle, K. R., Bech, J. N., Fiorina, P., Power, A., et al. (2026) · Kidney International Reports · doi:10.1016/j.ekir.2026.107083
Self-citation“Circulating Inflammation” and the Plasma Proteome in Heart Failure With Preserved Ejection Fraction
Vondriska, T. M., & Lefer, D. J. (2024) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2024.07.004
Therapie metabolischer Lebererkrankungen: Lebensstilintervention, Chirurgie und Pharmakotherapie
Huttasch, M., & KAHL, S. (2026) · Die Diabetologie · doi:10.1007/s11428-026-01502-6
Zhu, X., Wang, X., Zhang, P., Yang, Z., Zhao, N., Li, J., Shi, Y., Zhao, Y., & Ma, J. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1750615 · Cited by 1
Beyond Weight Loss: Skeletal Muscle Health During Incretin-Based Therapy in Patients with Diabesity
Mollero, E. L. M., Dozzani, I., Biamonte, E., Bendotti, G., Marzullo, P., Aimaretti, G., & Gallo, M. (2026) · Nutrients · doi:10.3390/nu18162654 · Cited by 2
“In patients with T2DM and chronic kidney disease (CKD), semaglutide was associated with reductions in absolute muscle mass alongside changes in relative indices, emphasizing the importance of how body composition outcomes are expressed [36].”
Manousopoulou, A., White, C. H., Hamal, S. A., Nihalani, R., Budoff, M. J., & Garbis, S. D. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.16.706239
Özdede, M., Yadigar, S., Güven, A. T., Akgür, S., Arslan, F., Sezen, M., Özcan, B., Ayaz, E. Y., Doğantekin, B., Atay, İ., et al. (2026) · Clinical Kidney Journal · doi:10.1093/ckj/sfag227 · Cited by 1
“…(ARBs) [ 9 ], sodium– glucose cotransporter-2 (SGLT2) inhibitors [ 10 , 11 ], glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide [ 12 ], and a novel nonsteroidal mineralocorticoid receptor antagonist (ns-MRA) finerenone [ 13 , 14 ], has been shown to improve renal and CVD…”
Stratégies thérapeutiques dans le traitement du diabète de type 2
Bordier, L., & Bauduceau, B. (2026) · EMC - Endocrinologie - Nutrition · doi:10.1016/s1155-1941(25)49531-6
de Sá, J. R. (2026) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2026-e008en
“This represents a critical missed opportunity, particularly in the current therapeutic landscape, in which GLP-1 receptor agonists 5 , sodium-glucose cotransporter-2 inhibitors (SGLT2i) 6–8 , and finerenone 9 have demonstrated consistent renoprotective benefits.”
Zeng, B., Hsu, C.-W., Hung, C., Yang, W.-C., Stubbs, B., Chen, Y.-W., Lei, W.-T., Chen, J.-J., Chen, T., Hsu, S., et al. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.104026
LeBleu, G., & Haj, F. G. (2026) · Journal of Biomedical Science · doi:10.1186/s12929-026-01282-7
“GLP-1 receptor agonists have established renal and cardiovascular protection as demonstrated by the FLOW trial, in which semaglutide significantly reduced major kidney disease events, cardiovascular events, and all-cause mortality in patients with T2DM and CKD [227].”
Rombach, J., Hannani, M. T., Henriksen, K., Bihlet, A. R., Bajaj, M., He, Y., Bay-Jensen, A.-C., Thudium, C. S., & Karsdal, M. (2026) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2026.09.007
Merker, L., Ebert, T., Schleicher, E. D., Isermann, B., & Guthoff, M. (2024) · Diabetologie und Stoffwechsel · doi:10.1055/a-2312-0591
Ikizler, T. A. (2025) · Kidney International · doi:10.1016/j.kint.2024.11.032
Miertová, Z., Blichová, T., Vnučák, M., et al. (2026) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000002097
麦, 麦. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1662319
Breakthrough drugs in the treatment of hypertension-related disease
Hoshide, S., Mogi, M., Shibata, S., Kishi, T., Usui, I., Ando, H., Nakagami, H., Nishiyama, A., Kario, K., & Japanese Society of Hypertension (JSH) Working Group on Emerging Pharmacological Therapies for Hypertension Management (2026) · Hypertension Research · doi:10.1038/s41440-026-02725-2
“In the SUSTAIN and FLOW trials conducted during the development of semaglutide for the treatment of type 2 diabetes, use of 1 mg/week of semaglutide lowered systolic blood pressure by approximately 2 mmHg and reduced body weight by approximately 3-5% [42, 43].”
Ye, L., & Yín, Y. (2026) · International Journal of Endocrinology · doi:10.1155/ije/1543983
From evidence to practice: Identifying candidates for semaglutide in chronic atherosclerotic disease
Maggioni, A. P., Orso, F., Lucci, D., Luca, L. D., & Colivicchi, F. (2026) · International Journal of Cardiology · doi:10.1016/j.ijcard.2026.134646
Barreto, E. F., Nieves, Y. A. G., Johnson, E. C., Eder, T. H., Gerberi, D., KASHANI, K. B., Kattah, A. G., Liu, K. D., May, H. P., McCoy, R. G., et al. (2026) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.70137 · Cited by 1
“There is growing evidence that SGLT2i and GLP-1 RA decrease CKD progression in patients with and without diabetes [9–11].”
Sarwal, A., Throolin, M. J., Wei, G., Nevers, M. R., Hartsell, S. E., Shen, J., Boucher, R. E., & Beddhu, S. (2026) · Primary care diabetes · doi:10.1016/j.pcd.2026.04.004
Popovic, D. S., Patoulias, D., Koufakis, T., et al. (2025) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2025.2516784
McGill, J. B., Green, J., Heerspink, H. J. L., Mann, J. F. E., Mottl, A. K., Rosenstock, J., Rossing, P. R., Vaduganathan, M., Nangaku, M., BRINKER, M. D., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70949
“…enzyme inhibitors [ACEis] and angiotensin-receptor blockers [ARBs]) [15], sodium–glucose cotransporter 2 inhibitors (SGLT2is) [16], glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) [17, 18] and the nonsteroidal mineralocorticoid receptor antagonist finerenone [19, 20].”
Self-citationKlotz, T. (2026) · Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie · doi:10.1055/a-2943-1080
Chen, S.-C., Huang, Y., Li, P.-Y., Chen, J.-C., Meyerowitz‐Katz, G., Yang, S., & Su, P. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71266
Vorwort zur Übersetzung der KDIGO-Leitlinie Diabetes und CKD
Ebert, T., Guthoff, M., Merker, L., Mertens, P. R., Schott, G., & Wanner, C. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2493-0919
“Hierbei wurde versucht, den Wortlaut der Leitlinie im Deutschen o d r r u c k z übereinstimmend begrüßen und in Ergänzung zu bestehenden Leitlinien für die Versorgung von Menschen mit Diabetes und Nie-renkrankheit sehr geeignet halten.”
Ding, M., Li, X., Wei, Y., Wang, J., Jiao, B., Li, C., Ma, W., Peng, Y., Shen, J., Yu, G., et al. (2026) · iScience · doi:10.1016/j.isci.2026.117174
Yue, H., Wang, Y., Guo, X., Sun, Y., Cheng, Y., Yan, P., Tan, Z., Han, C., & Wang, B. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118495
GLP-1 Receptor Agonists: Emerging Indications, Limitations, and Future Directions
Kaur, S., Hevia, L. C., Lee, D., Mesdaq, H., Wong, J., Diallo, F., Anil, S., Gharibyar, N., & Gharibyar, S. (2026) · Pharmacology & Pharmacy · doi:10.4236/pp.2026.172003
Renal Reinforcements: Slowing Diabetic Kidney Disease with Multiple New Agents
Thomas, R. L., & Rifkin, D. E. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000458
In remembrance: the life and legacy of George L. Bakris (1952–2024)
Sarafidis, P. A., Tsioufis, K., Burnier, M., Williams, B., Mancia, G., Weber, T., Stergiou, G. S., & the European Society of Hypertension and the International Society of Hypertension (2024) · Journal of Hypertension · doi:10.1097/hjh.0000000000003847
Zhu, L., Wang, K., Bian, C., Sheng, P., Yu, J., & An, X. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113525
Singhal, V., Gupta, A. A., & Srivastava, A. (2024) · IEEE Uttar Pradesh Section International Conference on Electrical, Electronics and Computer Engineering (UPCON) · doi:10.1109/upcon62832.2024.10983602
“This study expands on previous research by looking at how polymorphisms in the OPRD1 gene impact metabolic characteristics and beta-cell activity, with the objective of discovering novel therapeutic approaches for treating type 2 diabetes and obesity [3].”
Peptide hormone-based combinational pharmacotherapies for chronic metabolic diseases
Chui, Z. S. W., Xue, Y., Wu, X., & Xu, A. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100150
Heterogeneous treatment effects of GLP-1RA on kidney outcomes in patients with type 2 diabetes
Xu, Y., Maas, C. P., Huang, T., Wang, T., Créon, A., Sjölander, A., Fu, E. L., & Carrero, J. J. (2026) · Kidney International · doi:10.1016/j.kint.2026.06.041 · Cited by 1
Kuwagata, S., Chin‒Kanasaki, M., Yamada, A., et al. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70277
“Because the observation period was 2013 – 2024, SGLT2 inhibitors and GLP-1RAs were excluded from this de fi nition.”
InfluentialGLP-1 Receptor Agonists: Advances in Mechanism, Therapeutic Applications, and Future Perspectives
Pawar, M., Patil, C. S., Fakir, J. S., Pagar, D. S., & Mahajan, S. K. (2025) · BioMed Target Journal · doi:10.59786/bmtj.322
Perioperative Medication Management for Patients with Diabetes
Duggan, E. W., & Mazer, C. D. (2026) · Medical Clinics of North America · doi:10.1016/j.mcna.2025.11.010 · Cited by 1
de Moraes, T. P., Moura, A. F., Sposito, A. C., et al. (2026) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2025-0231pt
Toki, R., Sakamoto, M., & Takebayashi, T. (2026) · Diabetes Care · doi:10.2337/dci26-0098
Original rDNA Semaglutide Versus Synthetic Copies: Differences and Clinical Implications
Mohan, V., Kalra, S., Ahluwalia, A. I., Gangopadhyay, K. K., Bhattacharyya, A., Saboo, B., Kesavadev, J., Ramakrishnan, S., Lakhani, O., Nagendra, L., et al. (2026) · Cureus · doi:10.7759/cureus.114959
Qian, Z., Li, S., Yu-yang, L., Min‐lin, L., Huang, C., Min-hui, L., We, L., & Si-yuan, T. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118172 · Cited by 1
Novel Therapeutic Strategies for Obesity-Related Glomerulopathy
Liu, Y., Eirin, A., & Lerman, L. O. (2025) · Current Hypertension Reports · doi:10.1007/s11906-025-01357-0 · Cited by 2
“Indeed, semaglutide reduced the risk of major kidney outcomes in patients with T2DM and CKD [50].”
AbdelMagid, A. M., Kamel, A. M., & Farid, S. F. (2026) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.70142
“This finding aligns with recent data from the FLOW trial, where semaglutide benefits were consistent regardless of baseline albuminuria level [34].”
Chen, J., Tsai, M., Ho, W.-Y., Fang, Y.-W., Chen, M., & Hsiao, C.-C. (2025) · The American Journal of Medicine · doi:10.1016/j.amjmed.2025.12.011
Albuminuria a krónikus vesekárosodás kimutatására: biomarker és terápiás célpont
Vásárhelyi, B., & Tislér, A. (2026) · Orvosi Hetilap · doi:10.1556/650.2026.33622
Labate, A. M., Cimino, E., Giacomelli, L., Ettori, S., Oladeji, O. A., & Agosti, B. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146170 · Cited by 1
He, Z., Wang, X., Zhang, L., & Chen, X. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1882227
Avances farmacológicos en la lucha contra la obesidad
Portero, P. C. (2025) · Panorama actual del medicamento · doi:10.63105/49.481.1
Kidney Function and Mortality in Mexico: Prospective Study of 130,000 Adults
Aguilar-Ramirez, D. J., Tapia‐Conyer, R., Herrington, W. G., Ramírez-Reyes, R., Garcilazo‐Ávila, A., González-Carballo, C., Santacruz-Benítez, R., Bello‐Chavolla, O. Y., Bragg, F., Friedrichs, L. G., et al. (2026) · Kidney Medicine · doi:10.1016/j.xkme.2026.101398
Metabolic Syndrome: From Mechanisms to Therapeutic Interventions
Yan, M., & Xiang, Q. (2026) · MedComm · doi:10.1002/mco2.70934
Galati, G., & Андреевна, Г. О. (2025) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001677
Semaglutide cardiovascular outcomes align more closely with attained dose than achieved weight loss
Murugadoss, K., Venkatakrishnan, A., Gregg, C. J., & Soundararajan, V. (2026) · npj Cardiovascular Health · doi:10.1038/s44325-026-00146-1 · Cited by 3
“…failure with preserved ejection fraction (STEP-HFpEF), major kidney disease events in patients with type 2 diabetes and chronic kidney disease (FLOW), cardiovascular outcomes with oral semaglutide (SOUL), and walking limitations in patients with symptomaticperipheralarterydisease(STRIDE) 5 – 7 .”
Urinary Biomarkers for the Risk Assessment and Management of Heart Failure: Pearls and Pitfalls
Roehm, B. A., Vaggar, Y., Grodin, J. L., & Toto, R. D. (2026) · Current Heart Failure Reports · doi:10.1007/s11897-026-00774-9
Acute Interstitial Nephritis Associated with Oral Semaglutide
Elshayeb, M., Unwin, R. J., Petrosino, A., Kiliaris, M., Heptinstall, L., & Evans, R. D. R. (2026) · Kidney International Case Reports · doi:10.1016/j.kintcr.2026.100147
Cozzolino, M. G., Magagnoli, L., & Ciceri, P. (2025) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2025.2608857
Semaglutide and Risk of Pancreatic Cancer: A Meta‐Analysis of Randomised Trials
Chiang, C., Bahar, F., Chang, Y., Wang, T. H., Hsia, Y. P., & Chiang, C. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70980
Ahsan, M., Mazhar, S., Zafar, H., Mansoor, H., Nancy, F., Abbas, S. M., Shaikh, H., Khan, D. Z., Khan, A., Zahoor, B., et al. (2026) · Comprehensive physiology · doi:10.1002/cph4.70246
“This multinational, randomized, placebo-controlled study enrolled 3533 adults with T2D and moderate to severe CKD, many with significant albuminuria, and followed them for a median of 3.4 years before early termination due to clear efficacy (Perkovic et al. 2024).”
InfluentialHolst, K. K., Nordland, A., Furberg, J. F., Damgaard, L. H., & Pipper, C. B. (2026) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2026.2670526
“The trial objective was to investigate the ability of semaglutide - a once weekly glucagon like peptide-1 receptor agonist - to delay progression of kidney disease in a population with type 2 diabetes and chronic kidney disease at high risk of kidney disease progression.”
InfluentialJiang, W., Fukunaga, K., Kobayashi, T., Saheki, T., Yoshimura, T., Zhang, H., Ly, R., Imachi, H., & Murao, K. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188378
“Clinically, semaglutide reduces major kidney outcomes in patients with type 2 diabetes and chronic kidney disease [55], but the extent to which these benefits are mediated by direct modulation of renal lipid handling rather than systemic improvements in glycemia, body weight, hemodynamics, and…”
InfluentialPasam, R. T., Thompson, C. C., & Jirapinyo, P. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08583-8
Vergallo, R., & Volpe, M. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae567
Rebooting blood vessel repair: implications of the SEMA-VR CardioLink-15 trial
Verma, R., Verma, M., Park, B., Teoh, H., Quan, A., Connelly, K. A., & Hess, D. A. (2026) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001323
Xu, R. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70423
Anti-Obesity Medications in Longevity and Aesthetic Medicine
Bijoch, J. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15156026
“In the kidney, the FLOW trial of semaglutide in chronic kidney disease and T2DM was stopped early for efficacy, reporting a significant reduction in kidney-disease progression and cardiovascular and renal death [18].”
Precision medicine in type 2 diabetes: targeting SGLT2 inhibitor treatment for kidney protectionPreprint
Jansz, T. T., Young, K., Hopkins, R., et al. (2024) · medRxiv · doi:10.1101/2024.09.01.24312905
Grenet, G., Eskandari, R., Ko, J., Adams, S. P., Salzwedel, D. M., Heran, B. S., Ambasta, A., Bassett, K., & Thompson, W. (2026) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2026-006225
Huang, Z., THOMAS, R. J., Luo, Q., & Liu, Z. (2026) · Cardiac Research · doi:10.1097/re9.0000000000000028
Zarei, M., & Hajiani, Y. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02196-y
“…with type 2 diabetes and CKD (eGFR 25–75 mL/min/1.73 m²), semaglutide 1 mg once weekly reduced the composite endpoint of kidney failure, substantial loss of kidney function, and kidney-or cardio-vascular-related death by 24%, and lowered UACR by approximately 40% relative to baseline [112].”
InfluentialGroothof, D., Erler, N. S., & Bakker, S. J. L. (2026) · Open Research Europe · doi:10.12688/openreseurope.20428.2
Fioretti, F., Petrie, M. C., Dickert, N. W., & Butler, J. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.02.5086
López, J. P., Capote, P. A. C., Pozo, A. H., Castilla‐Guerra, L., Fernández‐García, J. C., Olmo, R. F., & Huete, M. J. E. (2025) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2025.501359 · Cited by 1
“Fuente: tabla realizada con datos de Muskiet et al. 58 , Marso et al. 59,60 , Bethel et al. 61 , Hernandez et al. 62 , Gerstein et al. 63 , Husain et al. 64 y Perkovic et al. 65 . placebo.”
Kylies, J., Kylies, D., Weisel, K. C., Wenzel, U. O., Huber, T. B., Viezens, L., & Leonhardt, L.-G. (2026) · Brain and Spine · doi:10.1016/j.bas.2026.106153
Claudel, S. E., & Verma, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71059
Murugadoss, K., Venkatakrishnan, A., & Soundararajan, V. (2026) · Biology Methods and Protocols · doi:10.1093/biomethods/bpag043
Xiao-yu, Z., Wu, Q., Lu, H.-L., Xie, J.-J., Zhang, Y., Xu, Y., Guo, M., & Teng, F. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02163-7 · Cited by 2
Metadata
- Authors
- Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., & Pratley, R.
- Affiliations
- University of Copenhagen (DK)
- Novo Nordisk A/S, Søborg, Denmark.
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-07-11
- Volume
- 391
- Issue
- 2
- Pages
- 109-121
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4398781461
- Cited by
- 2,099
- References
- 23
- Citations by year
- 2026: 953 · 2025: 863 · 2024: 281
- FWCI
- 551.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Digital Access to Libraries (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- semaglutide, chronic kidney disease, type 2 diabetes, renal failure, estimated glomerular filtration rate decline, cardiovascular mortality, albuminuria, GLP-1 receptor agonists, renal protection, cardiovascular outcomes, albumin-creatinine ratio, kidney transplantation, dialysis, anemia of chronic kidney disease, diabetic nephropathy, SGLT2 inhibitors
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Glucagon-Like Peptides, Female, Glomerular Filtration Rate, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Middle Aged, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.